William Hyman, M.D.
Department Internal Medicine
You have reached the Academic Profile.
For more information on the doctor and patient care, please visit the clinical profile.View Clinical Profile
William Hyman, M.D. is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology-Oncology. He serves as an oncology hospitalist for the Solid Tumor Inpatient Service at William P. Clements, Jr. University Hospital, caring for patients with various cancers.
Dr. Hyman received his medical degree from Baylor College of Medicine and completed internal medicine residency training at the University of Cincinnati Hospitals. He then completed advanced training through a fellowship in medical oncology at Baylor College of Medicine.
Certified by the American Board of Internal Medicine in internal medicine, medical oncology, and hospice and palliative medicine, he practiced general adult medical oncology in Tyler, Texas, and was the inaugural Medical Director of the UT Health Northeast MD Anderson Cancer Center. He joined the UT Southwestern faculty in 2018.
Dr. Hyman’s research focuses on clinical trials testing new therapies for cancer, which has resulted in multiple publications in peer-reviewed journals.
Dr. Hyman is a member of the Dallas County Medical Society, the Texas Society of Clinical Oncology, the Texas Medical Association, the American Society of Clinical Oncology, and the American College of Physicians-American Society of Internal Medicine. He is also a Fellow of the American College of Physicians.
Dr. Hyman and his wife enjoy exploring the Dallas area, especially visiting antique stores and spending time spoiling their grandkids.
- Medical School
- Baylor College of Medicine (1985)
- University of Cincinnati Medical Center (1988), Internal Medicine
- Baylor College of Medicine (1990), Medical Oncology
- Phase I-III Clinical Trials Testing New Therapies for Treating Cancer
- A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
- Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L Invest New Drugs 2012 Jun 30 3 1232-40
- Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
- Richards DA, Loesch D, Vukelja SJ, Wu H, Hyman WJ, Nieves J, Wang Y, Hu S, Shonukan OO, Tai DF Invest New Drugs 2011 Oct 29 5 963-70
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
- Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA J. Clin. Oncol. 2009 Mar 27 8 1177-83
- Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
- Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL, Boehm KA, Asmar L Clin Colorectal Cancer 2008 Nov 7 6 390-7
- Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
- Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L J. Clin. Oncol. 2006 Dec 24 34 5381-7
- Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.
- Drapkin R, Di Bella NJ, Faragher DC, Harden E, Matei C, Hyman W, Mirabel M, Boehm KA, Asmar L Clin Lymphoma 2003 Dec 4 3 169-75
- Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
- Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, Agura E, Duncan L, Hyman W, Roque T, Regan D, Schuster M, Dimitrov N, Garrison L, Lange M J. Clin. Oncol. 1999 Oct 17 10 3025-32
- SK&F107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies: a phase I trial.
- Nemunaitis J, Martin DE, Willis DL, Freed MI, Levitt B, Richards DA, Cox JV, Kimmel GT, Hyman WJ, Jorkasky DK, Brocks DR Am. J. Clin. Oncol. 1998 Apr 21 2 189-94
- American College of Physicians (2014)
- American Society of Clinical Oncology (1989)